Abstract
Overview
Introduction
The UI market is set to continue to grow over the next 6 years, reaching over
$2.5 billion in 2012, a 68% increase from 2006. Lifecycle management
strategies, novel formulations and follow-on products will drive the majority
of this growth, with key brands expected to be Pfizer' s Detrol LA
(tolterodine) and Toviaz (fesoterodine), GSK' s Vesicare (solifenacin), and
Novartis' Enablex (darifenacin).
Scope
- Analysis of patient potential, unmet needs and clinical trial design in UI.
- Overview of key marketed brands, late- and early-stage pipeline drugs, and
cell therapies.
- Indication-specific sales volume and value forecasts to 2016 of marketed
brands, generics, and key late-stage pipeline drugs.
- Identification of future market events that are expected to affect UI drug
revenues.
Highlights
Pfizer' s Detrol LA (tolterodine) will remain the market leading UI brand
through to 2012 when it comes off patent. At this point Detrol LA will be
followed by the other second generation anticholinergics, GSK' s Vesicare
(solifenacin), Novartis' Enablex (darifenacin) and Pfizer' s chemical
reformulation Toviaz (fesoterodine).
Following the patent expiry of the key brands, Detrol LA in 2012, and
Enablex/Vesicare in 2015, a novel mechanism of action is required for
long-term market growth. Examples of the possible mechanisms of action include
the NK-1 antagonists and the adrenergic modulators.
Datamonitor has identified a great untapped patient base in the US stress
urinary incontinence (SUI) market. A drug that could come into this market
would benefit from exclusivity, being the only treatment approved for SUI in
the US with a potential 28 million patient base.
Reasons to Purchase
- Benchmark key late-stage UI pipeline compounds against current market
leading brands.
- Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage
pipeline drugs and marketed brands.
- Understand unmet needs and opportunities in the UI market based on key
opinion leader comments.
| 
View Cart
